Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1636 1637 1653 1656 1663 1699 4100
This examiner grants 48% of resolved cases
Celine X. Qian is an examiner in Tech Center 4100 and Art Unit 1636. With 790 resolved cases, this examiner has an established record of managing patent applications. This volume of cases provides a dataset for practitioners to analyze when preparing for prosecution. The experience level suggested by 790 resolved cases indicates a consistent approach to the examination process within this specific tech center.
The examiner maintains an allowance rate of 47.6 percent, which is a key metric for assessing the likelihood of success. To improve these odds, practitioners should note the interview lift of 16.9 percent. This figure suggests that direct communication with the examiner can be an effective tool for resolving outstanding issues. The 16.9 percent lift is a factor to consider when deciding whether to request a formal interview during the prosecution cycle.
The median days to allowance for this examiner is 1340. This duration is an important benchmark for applicants to use when forecasting their patent portfolio timelines. When combined with the 47.6 percent allowance rate, the 1340 day median provides a view of the expected journey for an application. These data points allow for strategic planning and resource allocation in Art Unit 1636.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17761420 | CAP GUIDES AND METHODS OF USE THEREOF FOR RNA MAPPING | Non-Final OA | ModernaTX, Inc. |
| 18555503 | INHIBITORY RNA FOR THE CONTROL OF PHYTOPATHOGENS | Non-Final OA | The Regents of the University of California |
| 18265662 | INNATE IMMUNE CELL SILENCING BY SIRP-ALPHA ENGAGER | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17778254 | SPLIT-ENZYME SYSTEM TO DETECT SPECIFIC DNA IN LIVING CELLS | Non-Final OA | The Regents of the University of California |
| 16321777 | EXPRESSION OF PTEN-LONG WITH ONCOLYTIC VIRUSES | Final Rejection | OHIO STATE INNOVATION FOUNDATION |
| 18640031 | METHODS AND COMPOSITIONS FOR INHIBITING OXIDATIVE STRESS | Non-Final OA | President and Fellows of Harvard College |
| 18266423 | NOVEL SCREENING PLATFORM TO IDENTIFY IMMUNE MODULATORY AGENTS | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18064738 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | Non-Final OA | President and Fellows of Harvard College |
| 16976047 | EVOLVED CAS9 VARIANTS AND USES THEREOF | Non-Final OA | President and Fellows of Harvard College |
| 17681479 | NON-NATURALLY OCCURRING CAPSIDS FOR DELIVERY OF NUCLEIC ACIDS AND/OR PROTEINS | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 19345390 | ENCODING METHODS FOR MULTIPLEXED DETECTION OF TARGETS IN CELLS | Final Rejection | Singular Genomics Systems, Inc. |
| 18569059 | TYPE V RNA PROGRAMMABLE ENDONUCLEASE SYSTEMS | Non-Final OA | Bayer Aktiengesellschaft |
| 17814384 | VIRAL VECTORS FOR ENHANCED ULTRASOUND-MEDIATED DELIVERY TO THE BRAIN | Non-Final OA | California Institute of Technology |
| 18683988 | CRISPR-ASSOCIATED TRANSPOSONS AND USES THEREOF | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18566011 | METHODS AND COMPOSITIONS RELATED TO ENGINEERED BIOSENSORS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17929013 | METHODS FOR RAPID CLONING AND EXPRESSION OF HLA CLASS I CELLS | Final Rejection | Board of Regents, The University of Texas System |
| 17780421 | ENGINEERED CELLS FOR PRODUCTION OF CANNABINOIDS AND OTHER MALONYL-CoA-DERIVED PRODUCTS | Non-Final OA | Genomatica, Inc. |
| 18035240 | MODIFIED NK CELLS WITH REDUCED CCR5 EXPRESSION AND METHODS OF THEIR USE | Final Rejection | The United States of America, as represented by the Secretary, Dept. of Health and Human Services |
| 18306890 | CELLS WITH CD70 KNOCKOUT AND USES FOR IMMUNOTHERAPY | Non-Final OA | MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES |
| 17932239 | SYNTHETIC MODIFIED VACCINIA ANKARA (sMVA) BASED CORONAVIRUS VACCINES | Final Rejection | CITY OF HOPE |
| 17796284 | METHODS OF DIAGNOSING AND CLASSIFYING VIRAL INFECTIONS | Non-Final OA | MeMed Diagnostics Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy